Clinicopathological association of programmed death-ligand 1 ( PD-L1 ) expression in uterine cervical carcinomas: A cross-sectional observational study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Programmed death ligand (PD-L1) is expressed in a significant portion of cervical cancers, particularly in older patients and poorly differentiated tumors. This suggests PD-L1 immunotherapy may be a viable treatment option for PD-L1 positive cervical cancer.
Area Of Science
- Oncology
- Immunology
- Cancer Research
Background
- Programmed death ligand (PD-L1) binding to PD-1 on T-cells inhibits anti-tumor immune responses.
- Cancer cells exploit PD-L1 upregulation for immune evasion and tumor progression.
- PD-1/PD-L1 axis immunotherapy is FDA-approved for PD-L1 positive cervical cancer, a significant health issue in India, often diagnosed at advanced stages.
Purpose Of The Study
- To investigate the prevalence and patterns of PD-L1 expression in cervical cancer.
- To correlate PD-L1 expression with patient age and histological characteristics.
- To evaluate the potential of PD-L1 immunotherapy in cervical cancer treatment.
Main Methods
- A 5-year prospective, hospital-based study included 119 histologically confirmed cervical carcinoma cases.
- Tumor sections were stained for PD-L1 expression using the SP263 antibody on a Ventana Benchmark XT platform.
Main Results
- PD-L1 expression was detected in 35% (42/119) of cervical cancer cases.
- Higher PD-L1 positivity was observed in patients over 45 years (75.6%) compared to younger patients (24.4%).
- PD-L1 expression was more frequent in poorly differentiated carcinomas (37.5%) than in squamous cell carcinoma (31%) and adenocarcinoma (29%).
Conclusions
- A substantial percentage of cervical cancers exhibit PD-L1 expression.
- Increasing age and poor histological differentiation are associated with elevated PD-L1 levels.
- Findings support further investigation of anti-PD-L1 immunotherapy for PD-L1 positive cervical carcinomas.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.